Literature DB >> 9071734

A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors.

R Soong1, B J Iacopetta.   

Abstract

Evaluation of the clinical significance of p53 gene mutations requires molecular analysis of primary tumors from large series of patients with long follow-up periods. In this study, we describe a sensitive, rapid, nonisotopic and inexpensive procedure for the polymerase chain reaction (PCR)-single-stranded conformational polymorphism (SSCP) detection and subsequent sequencing of p53 mutations in formalin-fixed and paraffin-embedded tumor (PET) samples. To optimize this method, we used a panel of 34 mutations previously identified in this gene by isotopic PCR-SSCP analysis of frozen colorectal carcinomas. Identical SSCP band shifts were observed in PET sections from each of these frozen tumors, except for one case in which the tumor cell content was probably too low. All of the 34 mutations were detected by use of an optimized minigel SSCP/silver staining procedure. The total PCR-SSCP screening time with use of this protocol was less than 8 hours. An additional improvement was the use of multiplex SSCP to screen two p53 exons (5/7 and 6/8) simultaneously, thus effectively halving the amount of reagents and time required for mutation analysis. To identify the exact nucleotide alterations, mutant single-stranded DNA was excised from silver-stained SSCP gels, reamplified, and used as template in sequencing reactions. The PCR-SSCP procedure we describe can be performed in routine histopathology laboratories, requiring only a thermal cycler and minigel electrophoresis apparatus. Our results demonstrated the feasibility of conducting large retrospective analyses of p53 gene mutation status in archival tumor material. Studies of this kind should allow elucidation of the clinical role of p53 mutation in various human cancer types.

Entities:  

Mesh:

Year:  1997        PMID: 9071734

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue.

Authors:  M A Adank; E Brogi; F Bogomolniy; E A Wadsworth; K J Lafaro; C J Yee; T Kirchhoff; E J Meijers-Heijboer; N D Kauff; J Boyd; K Offit
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

2.  A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability.

Authors:  B Shannon; S Gnanasampanthan; J Beilby; B Iacopetta
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

3.  R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history.

Authors:  Fatih Eren; Mustafa Akkiprik; Ozlen Atuğ; Ozgür Sönmez; Gülgün Tahan; Filiz Ozdemir; Hülya Over Hamzaoğlu; Ciğdem Ataizi Celikel; Neşe Imeryüz; Erol Avşar; Ayşe Ozer
Journal:  Pathol Oncol Res       Date:  2010-03-23       Impact factor: 3.201

4.  Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.

Authors:  Rubén Ferrer-Luna; Manuel Mata; Lina Núñez; Jorge Calvar; Francisco Dasí; Eugenia Arias; José Piquer; Miguel Cerdá-Nicolás; Ana Lía Taratuto; Gustavo Sevlever; Bernardo Celda; Horacio Martinetto
Journal:  J Neurooncol       Date:  2009-07-12       Impact factor: 4.130

5.  Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas.

Authors:  Rona Ezer; Michelle Alonso; Elaine Pereira; Mimi Kim; Jeffrey C Allen; Douglas C Miller; Elizabeth W Newcomb
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma.

Authors:  F Mayall; G Jacobson; R Wilkins; B Chang
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

7.  Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer.

Authors:  Mustafa Akkiprik; Ozgur Sonmez; Bahadir M Gulluoglu; Hale B Caglar; Handan Kaya; Pakize Demirkalem; Ufuk Abacioglu; Meric Sengoz; Aydin Sav; Ayse Ozer
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

8.  A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.

Authors:  Vicki Whitehall; Kayla Tran; Aarti Umapathy; Fabienne Grieu; Chelsee Hewitt; Tiffany-Jane Evans; Tuty Ismail; Wei Qi Li; Peter Collins; Paul Ravetto; Barbara Leggett; Manuel Salto-Tellez; Richie Soong; Stephen Fox; Rodney J Scott; Alexander Dobrovic; Barry Iacopetta
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

9.  Mitochondrial DNA common deletion is not associated with thyroid, breast and colorectal tumors in Turkish patients.

Authors:  Cenk Aral; Mustafa Akkiprik; Handan Kaya; Cigdem Ataizi-Çelikel; Sinan Caglayan; Gökhan Ozisik; Hüseyin Baloglu; Ayse Ozer
Journal:  Genet Mol Biol       Date:  2010-03-01       Impact factor: 1.771

10.  Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Authors:  W Chua; D Goldstein; C K Lee; H Dhillon; M Michael; P Mitchell; S J Clarke; B Iacopetta
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.